Question · asked by 1 review
Tafamidis vs placebo: QoL
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Tafamidis vs placebo Quality of life (expressed as the change in 35‐Item Norfolk QOL‐DN total score) Scale from: ‐2 (best possible quality of life) to 138 (worst possible quality of life) · people with early‐stage TTR‐FAP Pharmacological treatment for familial amyloid polyneuropathy (2020) · Cochrane Headline outcomes only | no estimate extracted | 1 study · 125 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.